Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231279 · ClinicalTrials.gov registry record · Phase 3
Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency
A Phase 3 study, sponsored by Orlando Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT04231279 is a Phase 3 study that was terminated before completion, run by Orlando Health. The registered enrollment target is 27 participants.
The verdict
NCT04231279, a Phase 3 study, was terminated before completion, sponsored by Orlando Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a 3-year prospective study too identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy. An endoscopic pancreatic function test (ePFT) with secretin will be performed in children undergoing routine investigative EGD. The goal of this study is to identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy, who otherwise would be labelled as recurrent abdominal pain (RAP).
Interventions
- DRUG synthetic human secretin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04231279
The ClinicalTrials.gov registry entry for NCT04231279 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orlando Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which synthetic human secretin is the first listed.
NCT04231279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04231279 about?
NCT04231279 is a clinical study titled "Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency". This is a 3-year prospective study too identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy. An endoscopic pancreatic function test (ePFT) with secretin will be performed in children undergoing routine investigative EGD. The goal ...
What is the current status of trial NCT04231279?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2022-01-28. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT04231279?
The interventions under investigation include: synthetic human secretin (DRUG).
Who is sponsoring clinical trial NCT04231279?
This trial is sponsored by Orlando Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.